KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) EBITDA (2017 - 2025)

Bionano Genomics' EBITDA history spans 7 years, with the latest figure at -$8.5 million for Q3 2025.

  • For Q3 2025, EBITDA rose 80.55% year-over-year to -$8.5 million; the TTM value through Sep 2025 reached -$36.7 million, up 68.6%, while the annual FY2024 figure was -$104.0 million, 51.69% up from the prior year.
  • EBITDA for Q3 2025 was -$8.5 million at Bionano Genomics, down from -$7.8 million in the prior quarter.
  • Across five years, EBITDA topped out at -$7.8 million in Q2 2025 and bottomed at -$113.2 million in Q3 2023.
  • The 5-year median for EBITDA is -$28.8 million (2021), against an average of -$29.1 million.
  • The largest annual shift saw EBITDA plummeted 252.14% in 2023 before it soared 80.55% in 2025.
  • A 5-year view of EBITDA shows it stood at -$28.8 million in 2021, then plummeted by 30.38% to -$37.5 million in 2022, then surged by 33.51% to -$25.0 million in 2023, then soared by 52.15% to -$11.9 million in 2024, then rose by 28.5% to -$8.5 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's EBITDA are -$8.5 million (Q3 2025), -$7.8 million (Q2 2025), and -$8.5 million (Q1 2025).